Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gliwice – page 7

164 clinical trials in Gliwice, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gliwice at a glance
164
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

164 trials in Gliwice

Open in trial search

Plasma cell myeloma

Not yet recruiting

Teclistamab drug combination versus daratumumab and lenalidomide in MRD‑positive multiple myeloma patients after stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

B precursor type acute leukaemia

Not yet recruiting

Study of Tisagenlecleucel for Treating Adult Patients with Resistant or Relapsed B-cell Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Medical University Of Warsaw

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis acneiform

Not recruiting

A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Hoth Therapeutics Inc.

Osteoarthritis

Not recruiting

Study on the Effects of LNA043 for Patients with Knee Osteoarthritis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LNA043
  • Sponsor:Novartis Pharma AG

Osteoporosis

Not recruiting

Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Xentria Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Osteoarthritis

Not recruiting

Study on the Safety of RTX-GRT7039 and Ropivacaine Hydrochloride Injections for Patients with Moderate to Severe Knee Osteoarthritis Pain

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Resiniferatoxin
  • Sponsor:Gruenenthal GmbH

Bladder cancer

Not recruiting

Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Pfizer Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gliwice

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials focusing on chronic lymphocytic leukemia and various lymphomas, testing novel combination therapies and personalized treatment approaches.

  • B-cell lymphomas and leukemias
  • CAR T-cell therapy
  • Targeted therapies

Research includes assessment of venetoclax combinations and novel immunotherapy approaches for blood cancers.

02 Solid Tumors

Comprehensive studies examining treatments for advanced solid tumors, including breast, lung, and colorectal cancers.

  • Immunotherapy combinations
  • Targeted molecular therapies
  • Novel drug combinations

Investigations focus on improving survival outcomes through innovative treatment strategies.

03 Head and Neck Cancers

Clinical trials evaluating new approaches for head and neck squamous cell carcinoma and throat cancers using radiochemotherapy and immunotherapy.

  • Low-dose radiation therapy
  • Combination treatments
  • Novel immunotherapy agents

Studies aim to enhance treatment efficacy while minimizing side effects.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.